CN1615930A - Chinese medicine composition for treating thrombus obliterative angitis and its preparing method - Google Patents
Chinese medicine composition for treating thrombus obliterative angitis and its preparing method Download PDFInfo
- Publication number
- CN1615930A CN1615930A CNA2003101134556A CN200310113455A CN1615930A CN 1615930 A CN1615930 A CN 1615930A CN A2003101134556 A CNA2003101134556 A CN A2003101134556A CN 200310113455 A CN200310113455 A CN 200310113455A CN 1615930 A CN1615930 A CN 1615930A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- calomelas
- moschus
- mentioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a kind of Chinese medicine composition for treating thromboangitis obliterans and arteriosclerosis occlusion. It contains active components prepared with calomelas, sophora flower, peach kernel, croton, musk, etc. and the active components are matched with pharmaceutically acceptable excipient or carrier to prepare various preparation forms. The present invention has high curative rate, and no toxic side effect.
Description
One, technical field
The present invention relates to a kind of Chinese medicine composition, it can be used for the treatment of thromboangiitis obliterans, atherosclerotic occlusive disease.The invention still further relates to the preparation method of this Chinese medicine composition.
Two, background technology
The vasculitis full name is thromboangiitis obliterans, and age of onset generally between 20-45 year, is mainly in shank and foot, forms thrombosis mainly due to small artery in the limbs, causes blood supply insufficiency and causes.Atherosclerotic occlusive disease, clinical symptoms is basic identical with vasculitis, and this disease is more common in the middle-aged and elderly people more than 45 years old, and the male is more than the women, often complicated hypertension, coronary heart disease, cerebrovascular disease or diabetes.
The vasculitis traditional Chinese medical science claims that " necrosis disease " belongs to motherland's medical science BI-syndrome involved the blood vessels category, gangrene of toe disease.This is much sick more early stage from extremity, and ten refer to (toe) morbidity, show numb twinge, and spasm cramp, swelling, coolness of extremities or fever, red swelling of the skin be livid purple, fester and suppurate.The blood stasis obturation is obstructed in the lumen of vessels, causes the ischemia necrosis.At present, this disease is not still had satisfied treatment measure both at home and abroad, doctor trained in Western medicine is main to the Drug therapy of taking of this type of disease, and this type of therapy has certain curative effect only can give the effect that potent analgesic can not play treatment to III phase patient to I, II phase patient.Operative treatment has certain curative effect to I, II phase patient, and III phase patient will carry out amputation, stays deformity to the patient.It is main Therapeutic Method that the traditional Chinese medical science mainly adopts activating blood circulation to dissipate blood stasis to inferior disease, and effect obviously is better than simple western medical treatment.Chinese patent CN1062084A discloses a kind of preparation method of vasculitis fumigant, but fumigant has complex manufacturing technology to use shortcomings such as inconvenience.
So people still demand seek a kind of Chinese medicine that can simply be convenient to take and do not have bounce-back at a specified future date to thromboangiitis obliterans, the better making of atherosclerotic occlusive disease therapeutic effect.
Three, summary of the invention
[problem that will solve]
One of purpose of the present invention just provides a kind of Chinese medicine composition for the treatment of thromboangiitis obliterans, atherosclerotic occlusive disease, and this Chinese medicine can effectively improve the cure rate of thromboangiitis obliterans, atherosclerotic occlusive disease, nothing bounce-back at a specified future date.
The present invention is to Various Seasonal, body constitution, age, sex, the used Calomelas amount difference of the state of an illness, not only can realize best therapeutic effect but also can lower the toxicity of medicine.
Another object of the present invention provides the preparation method of this Chinese medicine composition.
[technical scheme]
The present invention is directed to the problems referred to above a kind of evident in efficacy and treatment thromboangiitis obliterans of short treating period, the medicine of atherosclerotic occlusive disease are provided.It is according to tcm theory, the medicine that adopts Calomelas, Flos Sophorae, Semen Persicae, Fructus Crotonis, Moschus and Nidus Vespae to be processed into through the science compatibility as raw material, the production technology of this medicine is simple, be easy to take, evident in efficacy, short treating period, is the medicine of a kind of ideal treatment thromboangiitis obliterans, atherosclerotic occlusive disease.
Specifically, the invention provides a kind of Chinese medicine composition for the treatment of thromboangiitis obliterans, atherosclerotic occlusive disease, it is made up of effective ingredient or effective ingredient and pharmaceutically acceptable carrier, it is characterized in that its contained effective ingredient made by following bulk drugs:
Calomelas 30-80 weight portion Flos Sophorae 30-50 weight portion
Semen Persicae 55-75 weight portion Fructus Crotonis 5-8 weight portion
Moschus 8-12 weight portion Nidus Vespae 67-100 weight portion
Preferably, raw materials of effective components medicine and consumption thereof are:
Calomelas 40-70 weight portion Flos Sophorae 35-45 weight portion
Semen Persicae 60-70 weight portion Fructus Crotonis 6-7 weight portion
Moschus 9-11 weight portion Nidus Vespae 80-90 weight portion
Wherein, Calomelas: be the chloride of hydrargyrum, be preferably calomel (Calomelas, Hg
2Cl
2).It has the external detoxicating and killing parasites, the effect of diuretic relieving constipation for oral administration.
Flos Sophorae: the dry flower and alabastrum for leguminous plant Chinese scholartree (Sophora japonica L.) has cooling blood for hemostasis, the effect of purging liver-fire.
Semen Persicae: be the seed of Folium rosae multiflorae plant peach (Prunus Persica (L.) Batch).Has activating blood circulation and dissipating phlegm, the effect of loosening bowel to relieve constipation.
Fructus Crotonis: be the fruit of euphorbia plant Fructus Crotonis (Croton tiglium L.), have drastic purgation and stagnate the detumescence of relieving oedema or abdominal distension through diuresis or purgation, the effect of eliminating phlegm sore-throat relieving.
Moschus: be the dry secretions in Cervidae (Cervidae) animal woods Moschus moschiferous (Moschus berezovskii Flerov), horse Moschus moschiferous (M.sifanicus Przewalski) or the ripe male body note capsule of former Moschus moschiferous (M.moschiferus L.), has the refreshment of having one's ideas straightened out, promoting blood circulation to restore menstrual flow, the effect of reducing swelling and alleviating pain.
Nidus Vespae: be Vespidae insecticide fruit hornet (Polistes olivaceous (DeGeer)), Japan long foot wasp (Polistes japonicus Saussure) or different abdomen wasp (Parapllybiavaria Fabricius) nest, have and dispel the wind, the merit poison, parasite killing, analgesic effect.
Chinese medicine composition of the present invention can be with above-mentioned raw materials with pharmaceutically acceptable carrier or excipient be made various routines dosage form for oral administration.
Above-mentioned prescription of the present invention can directly be pulverized as the active component of treatment thromboangiitis obliterans, atherosclerotic occlusive disease medicine.Described active component can be made various pharmaceutical formulations for oral administration such as powder, pill, tablet, granule, capsule, oral liquid etc. with pharmaceutically acceptable carrier or excipient composition.Wherein said pharmaceutically acceptable carrier and/or excipient can determine for the those of ordinary skill of pharmaceutical field.
Active ingredient in pharmaceutical of the present invention can prepare according to following method:
It contains the lower class step: take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption; Above-mentioned Chinese crude drug is dried and crushed into fine powder as active component; Then with above-mentioned active component with pharmaceutically acceptable carrier or excipient are prepared into various dosage forms.
(4) specific embodiment
Further describe the present invention by the following examples.
Embodiment 1
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 12 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
With the Calomelas mix homogeneously, put into Pagodatree Flower then behind the Semen Persicae porphyrize, even with the other medicines powder mixes again, make powder or incapsulate and make.Perhaps make other conventional dosage forms for oral administration.
Embodiment 2
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 9 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
Preparation method is with embodiment 1.
Embodiment 3
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 7.8 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
Preparation method is with embodiment 1.
Embodiment 4
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 6 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
Preparation method is with embodiment 1.
Embodiment 5
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 4.5 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
Preparation method is with embodiment 1.
Embodiment 6
Take by weighing these raw materials of traditional Chinese medicinal materials according to following consumption:
Calomelas 4.25 gram Flos Sophoraes 6 gram Semen Persicaes 9 grams
Fructus Crotonis 1 gram Moschus 1.5 gram Nidus Vespae 12 grams
Preparation method is with embodiment 1.
The characteristics of medicine of the present invention are: cure rate height, evident in efficacy, short treating period.Clinical Practice proves that the total effective rate of treatment thromboangiitis obliterans is 98%, and the total effective rate of treatment atherosclerotic occlusive disease is 98%.Specifically see as follows.
Test example 1, treatment thromboangiitis obliterans, atherosclerotic occlusive disease patient 100 routine clinical reports.
One, object of study
Thromboangiitis obliterans group: treatment group: 70 example age 21-45 years
Atherosclerotic occlusive disease group: treatment group: 30 example age 45-78 years
Above thromboangiitis obliterans, atherosclerotic occlusive disease patient all belong to angiopathy, the traditional Chinese medical science claims " necrosis disease " to belong to motherland's medical science BI-syndrome involved the blood vessels category, gangrene of toe disease, disease is seen: early stage many from extremity, ten refer to (toe) morbidity, show numb twinge, spasm cramp, swelling, coolness of extremities or fever, red swelling of the skin be livid purple, fester and suppurate.The blood stasis obturation is obstructed in the lumen of vessels, causes the ischemia necrosis.
Two, the method for administration and the course of treatment:
1, winter, the male, young body is strong, and III phase patient takes the medium person of embodiment 1,2 described medicine body constitution and uses embodiment 2-3 medicine; The weakling takes the described medicine of embodiment 4-5.
2, summer, generally take the described medicine of embodiment 3-6.
3, the women generally than male's class that descends, the equal patient of spring and autumn is than the class that descends winter, than improving a class summer.
When 4, the patient takes medicine, should be divided into three equal parts to medicine, every day, clothes were a, early 90 minutes ante cibum, took with boiled water.Should suck cold water after taking medicine.Three days is a course of treatment, obeys first course of treatment and should withdraw 4-7 days afterwards, and then take second course of treatment.
5, result
One, the present invention is 98% to the thromboangiitis obliterans total effective rate, sees Table one.
Two, the present invention is 98% to the total effective rate of atherosclerotic occlusive disease, sees Table two.
Table one the present invention is to the clinical observation of treatment thromboangiitis obliterans disease
| Group | Case load | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Thing of the present invention | ????70 | ????60 | ????65 | ????68 | ?????2 | ????98％ |
Table two the present invention is to the observation of treatment atherosclerotic occlusive disease
| Group | Case load | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Thing of the present invention | ????30 | ????28 | ????28 | ????29 | ?????1 | ????98％ |
Claims (4)
1. Chinese medicine composition for the treatment of thromboangiitis obliterans, atherosclerotic occlusive disease, it is made up of effective ingredient or effective ingredient and pharmaceutically acceptable carrier, it is characterized in that its contained effective ingredient made by following bulk drugs:
Calomelas 30-80 weight portion Flos Sophorae 30-50 weight portion
Semen Persicae 55-75 weight portion Fructus Crotonis 5-8 weight portion
Moschus 8-12 weight portion Nidus Vespae 67-100 weight portion
2. Chinese medicine composition according to claim 1 is characterized in that preparing raw materials of effective components medicine and consumption thereof and is:
Calomelas 40-70 weight portion Flos Sophorae 35-45 weight portion
Semen Persicae 60-70 weight portion Fructus Crotonis 6-7 weight portion
Moschus 9-11 weight portion Nidus Vespae 80-90 weight portion
3. the preparation method of claim 1 or 2 described Chinese medicine compositions, it contains the following step:
A) take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption;
B) with above-mentioned Chinese crude drug Calomelas, Flos Sophorae, Semen Persicae, Fructus Crotonis, Moschus parch porphyrize, the Moschus porphyrize is as active component;
C) above-mentioned active component is made various dosage forms with pharmaceutically accepting carrier.
4. the preparation method of claim 1 or 2 described Chinese medicine compositions, it contains the following step:
A) take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption;
B),, put into Flos Sophorae then and mix with other medicines again and mix thoroughly, as active component with Calomelas, Semen Persicae mix homogeneously with above-mentioned medical material parch porphyrize;
C) with above-mentioned active component with pharmaceutically can accept carrier and combine and make various types of dosage forms for oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101134556A CN1244345C (en) | 2003-11-12 | 2003-11-12 | Chinese medicine composition for treating thrombus obliterative angitis and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101134556A CN1244345C (en) | 2003-11-12 | 2003-11-12 | Chinese medicine composition for treating thrombus obliterative angitis and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1615930A true CN1615930A (en) | 2005-05-18 |
| CN1244345C CN1244345C (en) | 2006-03-08 |
Family
ID=34759953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101134556A Expired - Fee Related CN1244345C (en) | 2003-11-12 | 2003-11-12 | Chinese medicine composition for treating thrombus obliterative angitis and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1244345C (en) |
-
2003
- 2003-11-12 CN CNB2003101134556A patent/CN1244345C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244345C (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100388932C (en) | Method for preparing externally applied medicine for feet tinea | |
| CN1954866A (en) | Medicine for treating odontopathy and its preparation method | |
| CN1857449A (en) | Chinese medicine for treating puerperal hypogalactia | |
| CN1742919A (en) | Shuerjing Chinese medicine preparation and preparing method thereof | |
| CN1695682A (en) | External use preparation for treating rheumatisma and bone injuries | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1244345C (en) | Chinese medicine composition for treating thrombus obliterative angitis and its preparing method | |
| CN1294949C (en) | Chinese medicinal preparation for treating sexual dysfunction, menoxenia, aciesis and developing immunity | |
| CN1259078C (en) | Chinese medicine for treating women's chronic pelvic infection | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1167455C (en) | Medicine for treating acne and its preparing process | |
| CN112156225A (en) | Chitosan or and algal polysaccharide composite biological matrix liquid dressing gel preparation and preparation method thereof | |
| CN1939470A (en) | Chinese medicinal plaster with analgetic, hemostatic repercussive and sore-arresting functions | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN1879755A (en) | Chinese medicinal composition for preparing tumor-treating medicine | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN103861007A (en) | Chinese herbal medicine compound preparation for treating diarrhea of chicken | |
| CN1593564A (en) | Medicine for treating cold and its preparing process | |
| CN1552409A (en) | Medicine composition for preparing canker and preparing method thereof | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN1109550C (en) | Plaster for dispelling wind-evil and wetness-evil and stopping pain | |
| CN106728645A (en) | A kind of Traditional Chinese medicine compound composition of domestic animal lactagogue | |
| CN1958006A (en) | Preparation of Chinese traditional medicine for healthy chest and plumpy breasts | |
| CN1111419C (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular vessel apoplexy and premonitory apoplexy symptom and preparation method thereof | |
| CN1903255A (en) | Traditional Chinese medicine prepn. for treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060308 Termination date: 20141112 |
|
| EXPY | Termination of patent right or utility model |